ClinicalTrials.gg
Active, not recruitingNCT04573920AFFINITYUpdated Jun 1, 2026

Atrasentan in Patients With Proteinuric Glomerular Diseases

A Phase 2 interventional study of Atrasentan in IgA Nephropathy, Focal Segmental Glomerulosclerosis and Alport Syndrome, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Glomerulonephritis, IGA by Novartis — 9 open to participants now, 12 under way, 7 of them phase 3. Glomerulonephritis, IGA · Novartis.

Enrollment
8th of 14
103 · median 108
Started
2021
with 2 others
Phase 2
5 of 18
2 open now
Primary completion
2024-07
later than 0 of 11 live
Registered
6th of 18
by date

Among the 18 studies in Glomerulonephritis, IGA by Novartis, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2021, is one of 5 in phase 2, reaches primary completion later than 0 of the 11 other live ones, and was the 6th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

9 of the 18 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Glomerulonephritis, IGA by Novartis, or all of them as a file.
02

Study summary

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

Read the detailed description

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function. Cohorts will consist of patients with:

  • IgA nephropathy (IgAN) with urine protein:creatinine ratio (UPCR) of 0.5 to less than 1.0 g/g
  • Focal segmental glomerulosclerosis (FSGS)
  • Alport syndrome
  • Diabetic kidney disease (DKD) on top of background care of a RAS inhibitor and SGLT2 inhibitor

Additional cohorts may be added as data is available.

Approximately 100 patients will be enrolled in the study. Approximately 20 patients will be enrolled in each cohort to receive 0.75 mg atrasentan QD for 52 weeks. The study will also evaluate efficacy and safety of 1.5 mg atrasentan QD in FSGS subjects who received 0.75 mg atrasentan and it was well tolerated.

Patients will be allowed to continue into treatment extension and receive oral atrasentan QD for up to an additional 84 weeks (total maximum treatment of 188 weeks),

The primary objective of the study is to evaluate the effect of atrasentan on proteinuria (for IgAN, FSGS, and Alport syndrome patients) or albuminuria (for DKD patients) levels. Exploratory objectives include evaluating the change in kidney function over time as measured by eGFR, safety and tolerability. To facilitate study participation over this time period, where allowed by local regulations, options for remote study visits using telemedicine and home health may be offered.

03

Conditions studied

  • IgA Nephropathy
  • Focal Segmental Glomerulosclerosis
  • Alport Syndrome
  • Diabetic Kidney Disease
  • Diabetic Nephropathy Type 2
  • Immunoglobulin A Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and older for patients in the IgAN, FSGS, and Alport Syndrome cohorts
  • Age 18-70 years for patients in the DKD cohort
  • Receiving a maximally tolerated dose of RAS inhibitor therapy (ACEi or ARB) that has been stable for at least 12 weeks.
  • For patients enrolling in IgAN Cohort:

    1. -proven IgA nephropathy
    2. UPCR between 0.5 to less than 1.0 g/g
    3. Screening ≥ 30 mL/min/1.73 m2
  • For patients enrolling in FSGS Cohort:

    1. Biopsy-proven FSGS or documented genetic mutation in a podocyte protein associated with FSGS
    2. UPCR > 1.0 g/g
    3. Screening eGFR ≥ 30 mL/min/1.73 m2
    4. Subjects receiving systemic or other must be on a stable dose for at least 12 weeks.
    5. ≤ 40 kg/m2
  • For patients enrolling in Alport syndrome Cohort:

    1. Diagnosis of Alport syndrome by genetic testing
    2. UPCR > 0.5 g/g
    3. Screening eGFR ≥ 30 mL/min/1.73 m2
  • For patients enrolling in DKD Cohort:

    1. Diagnosis of type 2 diabetes mellitus
    2. UACR ≥ 0.5 g/g
    3. Screening eGFR ≥ 45 mL/min/1.73 m2
    4. Receiving a stable dose of SGLT2 inhibitor for at least 12 weeks
  • Willing and able to provide and comply with all study requirements

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of another cause of chronic kidney disease or another primary glomerulopathy.
  • History of kidney transplantation or other organ transplantation.
  • Except for FSGS patients, use of systemic medications, such as , for more than 2 weeks in the past 3 months.
  • Blood pressure above 150 mmHg systolic or 95 mmHg diastolic as evaluated by the Investigator.
  • History of heart failure or a previous hospital admission for fluid overload.
  • history of liver disease as assessed by the Investigator.
  • below 9 g/dL as measured by the Investigator or blood transfusion for anemia within the past 3 months.
  • Clinical diagnosis of nephrotic syndrome
  • within the past 5 years. Exception to the criteria include nonmelanoma skin cancer and curatively treated cervical carcinoma in situ.
  • For women, pregnant, breastfeeding, or intent to become pregnant during the study.
  • For men, intent to father a child or donate sperm during the study.
  • Recently received an agent.
  • Clinically significant unstable or uncontrolled medical condition as assessed by the Investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Atrasentan 0.75 mg

    Once daily oral administration of 0.75 mg atrasentan

    Drug: Atrasentan

  • Experimental
    Atrasentan 1.5 mg

    Once daily oral administration 1.5 mg atrasentan (FSGS cohorts only)

    Drug: Atrasentan

Interventions

  • Film-coated tablet

    Also known as: CHK-01, Atrasentan Hydrochloride, ABT-627

06

What researchers measure

Primary outcomes

  1. Change in proteinuria for IgAN, FSGS, and Alport syndrome patients receiving 0.75 mg atrasentan QD

    The change in urine protein:creatinine ratio (UPCR) from baseline to Week 12

    Time frame: Up to Week 12 or approximately 3 months

  2. Change in albuminuria for DKD patients

    The change in urine albumin:creatinine ratio (UACR) from baseline to Week 12

    Time frame: Up to Week 12 or approximately 3 months

  3. Change in proteinuria for FSGS patients at 1.5 mg dose

    The change in urine protein:creatinine ratio (UPCR) from baseline to Week 24

    Time frame: Up to Week 24 or approximately 6 months

  4. Change in proteinuria for FSGS patients at 1.5 mg dose

    The change in urine protein:creatinine ratio (UPCR) from baseline to Week 30

    Time frame: Up to Week 30 or approximately 7.5 months

07

Study locations

33 sites
  • Kidney Disease Medical Group
    Glendale, California 91206, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • North America Research Institute
    San Dimas, California 91773, United States
  • Stanford U School Of Medicine
    Stanford, California 94305, United States
  • Colorado Kidney Care Nephrology
    Denver, Colorado 80230, United States
  • Northwest Louisiana Nephrology Research
    Shreveport, Louisiana 71101-4440, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Uni of Minnesota Hos and Clinics
    Minneapolis, Minnesota 55455, United States
  • DaVita Clinical Research
    Las Vegas, Nevada 89146, United States
  • Mountain Kidney And Hyper Associa
    Asheville, North Carolina 28801, United States
  • Brookview Hills Research Assoc
    Winston-Salem, North Carolina 27103, United States
  • Baylor Scott and White
    Dallas, Texas 75246, United States
  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
  • Milwaukee Nephrologists SC
    Wauwatosa, Wisconsin 53226, United States
  • Novartis Investigative Site
    Gosford, New South Wales 2250, Australia
  • Novartis Investigative Site
    Herston, Queensland 4029, Australia
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    Reservoir, Victoria 3073, Australia
  • Novartis Investigative Site
    St Albans, Victoria 3021, Australia
  • Novartis Investigative Site
    St Leonards, 2065, Australia
  • Novartis Investigative Site
    Roma, RM 00165, Italy
  • Novartis Investigative Site
    Cheonan, Chungcheongnam-do 330-721, South Korea
  • Novartis Investigative Site
    Anyang-si, Gyeonggi-do 14068, South Korea
  • Novartis Investigative Site
    Seoul, Korea 02841, South Korea
  • Novartis Investigative Site
    Seoul, 03722, South Korea
  • Novartis Investigative Site
    Seoul, 134 727, South Korea
  • Novartis Investigative Site
    Port de Sagunt, Valencia 46520, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Lugo, 27004, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Majadahonda, 28222, Spain
  • Novartis Investigative Site
    Sheffield, South Yorkshire S10 2JF, United Kingdom
  • Novartis Investigative Site
    London, E1 1BB, United Kingdom
08

References and documents

Publications

  • Kuo JJ, Wu J, Gunawan MG, McConnell MT, Lester J, Naidu NA, Nieh CH, Surendradoss J, Kano T, Suzuki Y, Olson NE, Cox JH. Effects of Atrasentan on Kidney Gene Transcription, Mesangial Cell Proliferation, and Proteinuria in IgA Nephropathy. Kidney360. 2026 May 1;7(5):1003-1016. doi: 10.34067/KID.0000001000. Epub 2025 Dec 24. PubMed 41442197 ↗
  • Rheault MN. Treatment Approaches for Alport Syndrome. J Am Soc Nephrol. 2026 Jan 1;37(1):172-179. doi: 10.1681/ASN.0000000897. Epub 2025 Sep 12. PubMed 40938675 ↗
  • Lin J, Radhakrishnan J. What Are Baskets, Umbrellas, and Platforms Doing in Nephrology Clinical Trials? J Am Soc Nephrol. 2025 Feb 3;36(8):1652-1654. doi: 10.1681/ASN.0000000648. No abstract available. PubMed 39899371 ↗
  • Obadina M, Wilson S, Derebail VK, Little J. Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations. Kidney360. 2023 Jul 1;4(7):997-1005. doi: 10.34067/KID.0000000000000162. Epub 2023 May 31. PubMed 37254256 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jul 2024, 39 months.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2020
First posted
Oct 5, 2020
StartActual
Mar 15, 2021
Primary completionActual
Jul 2, 2024
CompletionEst.
Oct 27, 2026
Results delay requested
Jun 16, 2025
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04573920
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Mar 15, 2021
Primary completion
Jul 2, 2024
Completion
Oct 27, 2026 (estimated)
Last update
Jun 1, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atrasentan

Start the discussion